# Bioretec Oy > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/bioretec). ## Overview Bioretec is a Finnish medical device company that develops and manufactures absorbable orthopedic implants for adult and pediatric fracture fixation. Its product families, Activa and RemeOs™, are designed to support bone healing and then gradually dissolve, reducing the need for implant removal surgery. The company is headquartered in Tampere, Finland, with subsidiaries in Austria and the United States, and sells its products internationally. ## Products & services • Absorbable orthopedic implants for fracture fixation • RemeOs™ magnesium alloy implant platform • Activa self-reinforced PLGA polymer implants • Trauma Screw and related RemeOs™ indications • Product development, clinical evidence generation, and commercialization support - **RemeOs™ absorbable metal implants** (45%) — Magnesium alloy orthopedic implants designed to provide fixation and then absorb over time. - **Activa polymer implants** (40%) — Self-reinforced PLGA-based absorbable implants used in orthopedic procedures. - **Orthopedic trauma fixation products** (10%) — Implants and screws used in trauma and fracture repair applications. - **Clinical and commercialization support** (5%) — Training, surgeon education, and market development activities tied to product adoption. - Absorbable orthopedic implants for fracture fixation - RemeOs™ magnesium alloy implant platform - Activa self-reinforced PLGA polymer implants - Trauma Screw and related RemeOs™ indications - Product development, clinical evidence generation, and commercialization support ## Customers Bioretec sells to hospitals, surgeons, and healthcare systems that perform orthopedic procedures and need fixation devices for fracture healing. The company’s products are used in adult and pediatric orthopedics, with adoption driven by clinical performance, surgeon preference, and the desire to avoid removal surgery. Distribution partners and direct sales channels also matter because they help place the products into local healthcare markets. - **Hospitals and surgical centers** (primary) — Buy absorbable implants for trauma and fracture fixation procedures. - **Orthopedic surgeons** (primary) — Select Activa and RemeOs™ products based on handling, healing, and removal-avoidance benefits. - **Pediatric orthopedics** (secondary) — Uses absorbable fixation to reduce the need for secondary removal surgery in younger patients. - **Distribution partners** (secondary) — Buy or represent products in markets outside the U.S. and support local commercialization. - **Healthcare systems** (secondary) — Adopt the products when value-based care and reduced procedure burden are important. - Hospitals and surgical centers buying implants for orthopedic procedures - Orthopedic surgeons seeking absorbable fixation options - Pediatric orthopedics customers needing implants that avoid removal surgery - Health systems focused on patient outcomes and lower follow-up burden - Distribution partners that place products in local markets ## Geography Bioretec is headquartered in Tampere, Finland and operates through subsidiaries in Austria and the United States. Its implants are sold worldwide in more than 40 countries, with commercial priorities centered on the U.S. and selected markets outside the U.S. Geography matters because regulatory approvals, distributor selection, and surgeon education differ by market and directly affect adoption. - Headquartered in Tampere, Finland - Subsidiaries in Austria and the United States - Products sold in over 40 countries worldwide - U.S. is a key commercial focus for direct distribution - Outside the U.S., growth depends on distribution partners and approvals ## Strategy Bioretec’s strategy centers on expanding the RemeOs™ platform, generating clinical evidence, and building commercial scale in the U.S. and selected international markets. The company also aims to introduce at least one new product or indication every 12–18 months, using R&D and surgeon engagement to strengthen adoption and support long-term commercialization. - **Expand the RemeOs™ product family** (medium-term) — New products and indications broaden the addressable market and deepen the platform. - **Strengthen U.S. commercialization** (short-term) — Direct distribution and surgeon education can improve adoption in the largest target market. - **Improve outside-U.S. market execution** (short-term) — Partner selection and market-specific launches are needed to convert approvals into sales. - **Generate clinical and economic evidence** (medium-term) — Evidence supports surgeon adoption, reimbursement discussions, and regulatory credibility. - Expand RemeOs™ through new products and indications - Build U.S. direct distribution and surgeon engagement - Upgrade outside-U.S. partner selection and targets - Invest in clinical and economic evidence generation - Grow commercial scale while maintaining product margin discipline ## Risks Bioretec depends on regulatory approvals, surgeon adoption, and successful commercialization of a relatively novel implant platform, so execution risk is high. The business also faces typical medtech risks such as product quality, clinical evidence requirements, distributor dependence outside the U.S., and the possibility that adoption of absorbable implants develops more slowly than expected. - **Regulatory and approval risk** [high] — Implants must clear country-specific regulatory pathways before sales can expand. - **Commercial adoption risk** [high] — Surgeons may be slow to switch from established metal implants to absorbable alternatives. - **Distributor execution risk** [medium] — Outside the U.S., sales depend on partner selection, incentives, and local execution. - **Product quality and clinical risk** [high] — Implants are used in surgery, so defects or adverse events could affect reputation and approvals. - **Innovation pipeline risk** [medium] — Growth depends on timely new products and indications from the R&D pipeline. - Regulatory approvals are required before commercialization in each market - Clinical adoption depends on surgeon confidence and evidence generation - Distributor performance outside the U.S. can limit market access - Product quality or safety issues could damage trust and approvals - Novel implant technology may take time to gain broad acceptance ## Accounting Bioretec’s reported numbers are sensitive to revenue timing around product shipments, distributor arrangements, and market launch milestones. Investors should also watch capitalization and impairment judgments tied to development work, because the value of the RemeOs™ and Activa platforms depends on future commercialization success and regulatory progress. - **Revenue recognition** — Can shift quarterly revenue timing around product launches and distributor orders - **Development costs and capitalization** — Affects operating profit and asset balances - **Impairment of development assets** — Could materially affect earnings and equity - **Inventory valuation** — May create write-downs or margin volatility - **Foreign currency translation** — Can affect reported revenue, expenses, and equity - Revenue timing may vary with direct sales, distributor shipments, and launch milestones - Development spending and capitalization judgments affect reported operating results - Intangible asset or project impairment risk depends on commercialization success - Inventory valuation matters for specialized implant products with launch timing uncertainty - Foreign currency translation can affect reported results across Finland, the U.S., and Austria --- *Last updated: 2026-08-11T04:04:51.250814+00:00*